Seres Therapeutics
MCRB
91 hedge funds and large institutions have $916M invested in Seres Therapeutics in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 14 reducing their positions, and 6 closing their positions.
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
207% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 14
20% more funds holding
Funds holding: 76 → 91 (+15)
11% more capital invested
Capital invested by funds: $822M → $916M (+$93.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
68% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $5.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$27.9M |
| 2 |
CCI
Columbus Circle Investors
|
+$10.8M |
| 3 |
Jennison Associates
New York
|
+$7.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.75M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$6.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$17.4M |
| 2 |
BG
BlackRock Group
London,
United Kingdom
|
-$5.68M |
| 3 |
BM
Bridger Management
New York
|
-$2.55M |
| 4 |
O
OrbiMed
New York
|
-$2.37M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.43M |
MCRB Hedge Fund Activity: Q2 2016 in Review
91 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2016, worth a combined $916M — up 11% from $822M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new MCRB positions and 6 closed out — a net gain of 17 holders — while 43 added to existing stakes and 14 trimmed.
The largest buyer was Federated Hermes, adding an estimated $27.9M. The largest seller was BlackRock Advisors, cutting an estimated $17.4M.
- 91 institutional investors held Seres Therapeutics (MCRB) as of Q2 2016, up from 76 in Q1 2016.
- Funds reported $916M of Seres Therapeutics stock for Q2 2016, up 11% quarter-over-quarter.
- 23 funds opened new Seres Therapeutics positions in Q2 2016 and 6 closed out, a net change of +17 holders.
- The largest Seres Therapeutics buyer in Q2 2016 was Federated Hermes, an estimated $27.9M added.
- The largest Seres Therapeutics seller in Q2 2016 was BlackRock Advisors, an estimated $17.4M sold.
Based on aggregated 13F filings for Q2 2016.